

Erratum to: Peginterferon and Entecavir Combination Therapy Improves Outcome of Non–Early Response Hepatitis B e Antigen–Positive Patients

Lu Chen,¹ Lanyi Lin,¹ Huijuan Zhou,¹ Weiliang Tang,¹ Hui Wang,¹ Wei Cai,¹ Shisan Bao,² Simin Guo,¹ and Qing Xie¹

¹Department of Infectious Disease, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China, and ²Discipline of Pathology, School of Medical Science, Charles Perkins Centre, The Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia

Open Forum Infectious Diseases, Volume 7, Issue 11, November 2020, ofaa462, <https://doi.org/10.1093/ofid/ofaa462>

Published: 30 September 2020

In the original publication of this article [Peginterferon and Entecavir Combination Therapy Improves Outcome of Non–Early Response Hepatitis B e Antigen–Positive Patients, *Open Forum Infectious Diseases*, Volume 7, Issue 11, November 2020, ofaa462], several final changes from the authors were missed, which affected results data and authorship information.

1. The authors Shisan Bao, Simin Guo, and Qing Xie should have received a statement of equal contribution for this article.

2. Results data regarding HBsAg decline for groups A and B at 48 and 96 weeks of monotherapy or combination therapy were also incorrect on first publication and have since been corrected as followed:

A more profound difference in HBsAg level was detected with prolonged treatment (48 weeks: group A vs group B, 3.567 log₁₀ IU/mL vs 3.039 log₁₀ IU/mL; P = .0174; 96 weeks: group A vs group B, 3.344 log₁₀ IU/mL vs 2.266 log₁₀ IU/mL; P = .0012) (Figure 3B).

These have been corrected in the original article, and the publisher regrets this error.

Correspondence: Qing Xie, Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200020, China (xieqingrjh@163.com).

Open Forum Infectious Diseases®2021

© Infectious Diseases Society of America 2021. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com <https://doi.org/10.1093/ofid/ofab354>